Novo Integrated Sciences, Inc. (NVOS)
USD 0.01
(111.54%)
USD 0.01
(111.54%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.06 Million USD | -41.23% |
| 2022 | 18.82 Million USD | 3.7% |
| 2021 | 18.15 Million USD | 211.98% |
| 2020 | 5.81 Million USD | -13.53% |
| 2019 | 6.72 Million USD | 47.24% |
| 2018 | 4.57 Million USD | -53.38% |
| 2017 | 9.8 Million USD | 49765.6% |
| 2016 | 19.65 Thousand USD | 49.83% |
| 2015 | 13.12 Thousand USD | -97.98% |
| 2014 | 648.26 Thousand USD | -50.35% |
| 2013 | 1.3 Million USD | 56.94% |
| 2012 | 831.89 Thousand USD | -64.66% |
| 2011 | 2.35 Million USD | -12.14% |
| 2010 | 2.67 Million USD | 77.72% |
| 2009 | 1.5 Million USD | 3.33% |
| 2008 | 1.45 Million USD | 41.84% |
| 2007 | 1.02 Million USD | 121.68% |
| 2006 | 464.02 Thousand USD | -3.07% |
| 2005 | 478.72 Thousand USD | 14.52% |
| 2004 | 418.04 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 25.66 Million USD | 96.52% |
| 2024 Q1 | 13.96 Million USD | 26.18% |
| 2024 Q2 | 13.05 Million USD | -6.46% |
| 2023 Q2 | 9.52 Million USD | -44.17% |
| 2023 Q1 | 17.06 Million USD | -9.36% |
| 2023 FY | 11.06 Million USD | -41.23% |
| 2023 Q3 | 9.45 Million USD | -0.76% |
| 2023 Q4 | 11.06 Million USD | 17.03% |
| 2022 Q2 | 25.8 Million USD | 27.33% |
| 2022 Q4 | 18.82 Million USD | -31.21% |
| 2022 FY | 18.82 Million USD | 3.7% |
| 2022 Q1 | 20.26 Million USD | 11.63% |
| 2022 Q3 | 27.36 Million USD | 6.04% |
| 2021 FY | 18.15 Million USD | 211.98% |
| 2021 Q3 | 5.61 Million USD | -1.83% |
| 2021 Q4 | 18.15 Million USD | 223.18% |
| 2021 Q1 | 5.68 Million USD | -2.27% |
| 2021 Q2 | 5.72 Million USD | 0.61% |
| 2020 Q2 | 6.33 Million USD | -2.92% |
| 2020 Q4 | 5.81 Million USD | -2.59% |
| 2020 FY | 5.81 Million USD | -13.53% |
| 2020 Q3 | 5.97 Million USD | -5.77% |
| 2020 Q1 | 6.53 Million USD | -2.95% |
| 2019 FY | 6.72 Million USD | 47.24% |
| 2019 Q1 | 4.54 Million USD | -0.56% |
| 2019 Q2 | 4.25 Million USD | -6.43% |
| 2019 Q3 | 6.36 Million USD | 49.76% |
| 2019 Q4 | 6.72 Million USD | 5.67% |
| 2018 Q4 | 4.57 Million USD | 0.31% |
| 2018 Q3 | 4.55 Million USD | -3.44% |
| 2018 Q2 | 4.71 Million USD | -49.47% |
| 2018 Q1 | 9.33 Million USD | -4.73% |
| 2018 FY | 4.57 Million USD | -53.38% |
| 2017 Q1 | 19.65 Thousand USD | 548.99% |
| 2017 Q4 | 9.8 Million USD | -1.36% |
| 2017 Q3 | 9.93 Million USD | 188544.8% |
| 2017 Q2 | 5268.00 USD | -73.2% |
| 2017 FY | 9.8 Million USD | 49765.6% |
| 2016 FY | 19.65 Thousand USD | 49.83% |
| 2016 Q2 | 26.81 Thousand USD | 104.36% |
| 2016 Q3 | 9393.00 USD | -64.97% |
| 2016 Q4 | 3029.00 USD | -67.75% |
| 2016 Q1 | 13.12 Thousand USD | 9.42% |
| 2015 FY | 13.12 Thousand USD | -97.98% |
| 2015 Q3 | 55.77 Thousand USD | -44.91% |
| 2015 Q1 | 648.26 Thousand USD | -9.19% |
| 2015 Q2 | 101.25 Thousand USD | -84.38% |
| 2015 Q4 | 11.99 Thousand USD | -78.5% |
| 2014 FY | 648.26 Thousand USD | -50.35% |
| 2014 Q3 | 1.34 Million USD | 10.21% |
| 2014 Q1 | 1.3 Million USD | 3.38% |
| 2014 Q4 | 713.9 Thousand USD | -46.93% |
| 2014 Q2 | 1.22 Million USD | -6.52% |
| 2013 FY | 1.3 Million USD | 56.94% |
| 2013 Q4 | 1.26 Million USD | 31.96% |
| 2013 Q3 | 957.03 Thousand USD | -1.72% |
| 2013 Q2 | 973.75 Thousand USD | 17.05% |
| 2013 Q1 | 831.89 Thousand USD | 4.39% |
| 2012 Q4 | 796.92 Thousand USD | 18.32% |
| 2012 Q2 | 2.05 Million USD | -12.7% |
| 2012 Q1 | 2.35 Million USD | 4.88% |
| 2012 FY | 831.89 Thousand USD | -64.66% |
| 2012 Q3 | 673.54 Thousand USD | -67.22% |
| 2011 Q4 | 2.24 Million USD | 9.08% |
| 2011 Q2 | 2.71 Million USD | 1.46% |
| 2011 Q1 | 2.67 Million USD | 53.57% |
| 2011 Q3 | 2.05 Million USD | -24.3% |
| 2011 FY | 2.35 Million USD | -12.14% |
| 2010 Q1 | 1.5 Million USD | 0.62% |
| 2010 FY | 2.67 Million USD | 77.72% |
| 2010 Q4 | 1.74 Million USD | 1.95% |
| 2010 Q3 | 1.71 Million USD | 7.72% |
| 2010 Q2 | 1.58 Million USD | 5.37% |
| 2009 Q4 | 1.49 Million USD | -0.07% |
| 2009 FY | 1.5 Million USD | 3.33% |
| 2009 Q1 | 1.45 Million USD | 10.74% |
| 2009 Q2 | 1.42 Million USD | -2.45% |
| 2009 Q3 | 1.49 Million USD | 5.33% |
| 2008 Q4 | 1.31 Million USD | 4.67% |
| 2008 Q1 | 1.02 Million USD | 11.0% |
| 2008 Q2 | 1.1 Million USD | 7.46% |
| 2008 FY | 1.45 Million USD | 41.84% |
| 2008 Q3 | 1.25 Million USD | 13.88% |
| 2007 Q2 | 612.61 Thousand USD | 32.02% |
| 2007 Q4 | 926.74 Thousand USD | 10.91% |
| 2007 Q1 | 464.02 Thousand USD | 43.01% |
| 2007 Q3 | 835.6 Thousand USD | 36.4% |
| 2007 FY | 1.02 Million USD | 121.68% |
| 2006 FY | 464.02 Thousand USD | -3.07% |
| 2006 Q4 | 324.47 Thousand USD | -55.04% |
| 2006 Q3 | 721.7 Thousand USD | 38.18% |
| 2006 Q2 | 522.3 Thousand USD | 9.1% |
| 2006 Q1 | 478.72 Thousand USD | 16.33% |
| 2005 FY | 478.72 Thousand USD | 14.52% |
| 2005 Q2 | 238.72 Thousand USD | 0.0% |
| 2005 Q3 | 328.14 Thousand USD | 37.46% |
| 2005 Q4 | 411.53 Thousand USD | 25.41% |
| 2004 FY | 418.04 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acadia Healthcare Company, Inc. | 2.47 Billion USD | 99.552% |
| Addus HomeCare Corporation | 317.73 Million USD | 96.518% |
| AirSculpt Technologies, Inc. | 129.56 Million USD | 91.46% |
| Amedisys, Inc. | 940.38 Million USD | 98.823% |
| American Oncology Network, Inc. | 368.72 Million USD | 96.999% |
| Astrana Health, Inc. | 522.59 Million USD | 97.883% |
| Aveanna Healthcare Holdings Inc. | 1.76 Billion USD | 99.373% |
| IMAC Holdings, Inc. | 1.89 Million USD | -483.307% |
| biote Corp. | 191.84 Million USD | 94.233% |
| Cryo-Cell International, Inc. | 72.25 Million USD | 84.687% |
| Cross Country Healthcare, Inc. | 205.92 Million USD | 94.627% |
| COMPASS Pathways plc | 50.24 Million USD | 77.979% |
| DocGo Inc. | 185.28 Million USD | 94.029% |
| The Ensign Group, Inc. | 2.68 Billion USD | 99.587% |
| Healthcare Services Group, Inc. | 346.56 Million USD | 96.808% |
| InnovAge Holding Corp. | 247.85 Million USD | 95.536% |
| Assure Holdings Corp. | 22.84 Million USD | 51.578% |
| The Joint Corp. | 62.37 Million USD | 82.263% |
| LifeStance Health Group, Inc. | 804.27 Million USD | 98.624% |
| Mobile-health Network Solutions Class A Ordinary Shares | 3.81 Million USD | -190.304% |
| ModivCare Inc. | 1.61 Billion USD | 99.313% |
| NewGenIvf Group Limited | 1.24 Million USD | -791.224% |
| Option Care Health, Inc. | 1.9 Billion USD | 99.42% |
| P3 Health Partners Inc. | 427.3 Million USD | 97.411% |
| P3 Health Partners Inc. | 427.3 Million USD | 97.411% |
| The Pennant Group, Inc. | 394.17 Million USD | 97.193% |
| Surgery Partners, Inc. | 3.65 Billion USD | 99.697% |
| Syra Health Corp. Class A Common Stock | 910.07 Thousand USD | -1115.725% |
| Talkspace, Inc. | 23.57 Million USD | 53.069% |
| Talkspace, Inc. | 23.57 Million USD | 53.069% |
| The Oncology Institute, Inc. | 162.39 Million USD | 93.187% |
| The Oncology Institute, Inc. | 162.39 Million USD | 93.187% |